Drug reference

Vecuronium bromide

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1431, 1432

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Neuromuscular blockade (intermediate duration) during surgery and intubation ▶INITIALLY BY INTRAVENOUS INJECTION ▶Adult: 80–100 micrograms/kg; (by intravenous injection) maintenance 20–30 micrograms/kg, adjusted according to response, max. 100 micrograms/kg in caesarean section, alternatively (by intravenous infusion) maintenance 0.8–1.4 micrograms/kg/minute, adjusted according to response DOSES AT EXTREMES OF BODY-WEIGHT ▶To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal body-weight.

PDF page 1431

Safety

Interactions

→Appendix 1: neuromuscular blocking drugs, non-depolarising

PDF page 1431

Side Effects

▶Uncommon Procedural complications ▶Rare or very rare Angioedema. face oedema. paralysis

PDF page 1431

Hepatic Impairment

Manufacturer advises caution in signiﬁcant impairment.

PDF page 1431

Renal Impairment

Use with caution.

PDF page 1431

Dose and formulations

Directions For Administration

Reconstitute each vial with 5 mL Water for Injections to give 2 mg/mL solution; alternatively reconstitute with up to 10 mL Glucose 5% or Sodium Chloride 0.9% or Water for Injections—unsuitable for further dilution if not reconstituted with Water for Injections. For continuous intravenous infusion, dilute reconstituted solution to a concentration up to 40 micrograms/mL with Glucose 5% or Sodium Chloride 0.9%; reconstituted solution can also be given via drip tubing.

PDF page 1431

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Powder for solution for injection ▶Vecuronium bromide (Non-proprietary) Vecuronium bromide 10 mg Vecuronium bromide 10mg powder for solution for injection vials | 10 vial P £57.85 (Hospital only) 1.2 Neuromuscular blockade reversal Neuromuscular blockade reversal Neuromuscular blockade reversal Anticholinesterases Anticholinesterases reverse the effects of the non- depolarising (competitive) neuromuscular blocking drugs such as pancuronium bromide p. 1409 but they prolong the action of the depolarising neuromuscular blocking drug suxamethonium chloride p. 1407. Anaesthesia Neostigmine p. 1188 is used speciﬁcally for reversal of non-depolarising (competitive) blockade. It acts within one minute of intravenous injection and its effects last for 20 to 30 minutes; a second dose may then be necessary. Glycopyrronium bromide p. 1405 or alternatively atropine sulfate p. 1404, given before or with neostigmine, prevent bradycardia, excessive salivation, and other muscarinic effects of neostigmine. Other drugs for reversal of neuromuscular blockade Sugammadex below is a modiﬁed gamma cyclodextrin that can be used for rapid reversal of neuromuscular blockade induced by rocuronium bromide p. 1409 or vecuronium bromide p. 1409. In practice, sugammadex is used mainly for rapid reversal of neuromuscular blockade in an emergency. ANTICHOLINESTERASES

PDF page 1432

Dose text by age group

Adult

80–100 micrograms/kg; (by intravenous

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1431

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Vecuronium bromide

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1431, 1432

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

PDF page 1431

Safety

Interactions

→Appendix 1: neuromuscular blocking drugs, non-depolarising

PDF page 1431

Side Effects

▶Uncommon Procedural complications ▶Rare or very rare Angioedema. face oedema. paralysis

PDF page 1431

Hepatic Impairment

Manufacturer advises caution in signiﬁcant impairment.

PDF page 1431

Renal Impairment

Use with caution.

PDF page 1431

Dose and formulations

Directions For Administration

PDF page 1431

Medicinal Forms

PDF page 1432

Dose text by age group

Adult

80–100 micrograms/kg; (by intravenous

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1431

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.